PERSPECTA

News from every angle

← Back to headlines

Matinas BioPharma Receives NYSE Notice Over Equity Shortfall

Matinas BioPharma has received a notice from the NYSE regarding an equity shortfall, granting the company until 2027 to comply with the exchange's listing requirements.

26 Jun, 21:38 — 26 Jun, 21:38
PostShare

Sources

Showing 1 of 1 sources
seeking-alphaMixed2d ago

Matinas BioPharma faces NYSE notice over equity shortfall; gets until 2027 to comply

Read full article →

Related Stories

Amazon's First Customer Receipt Goes Viral, Bezos and Musk React

just now

Illicit Cigarettes Seized in Isabela, Philippines, with P82.33M in Tax Liabilities

just now

Babcock University Warns Public Against Fake Certificates

just now

Riga Central Market Board Resigns Amid Meat Pavilion Crisis

6m ago